BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:10 PM
 | 
Apr 29, 2010
 |  BC Extra  |  Clinical News

Taspoglutide meets T-emerge 3 endpoint

Ipsen Group (Euronext:IPN) said partner Roche (SIX:ROG; OTCQX:RHHBY) reported that subcutaneous weekly taspoglutide plus metformin and Actos pioglitazone met the primary endpoint...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >